Proceeds From Artes Medical IPO To Fund ArteFill Wrinkle-Filler Launch
This article was originally published in The Gray Sheet
Executive Summary
Artes Medical will fund the launch of its ArteFill injectable wrinkle filler in the first quarter of 2007 with the proceeds of an initial public stock offering completed Dec. 20
You may also be interested in...
Introducing Spheris Medical
Artes Medical creates a wholly-owned subsidiary called Spheris Medical June 12 to develop non-aesthetic applications of its ArteFill non-resorbable, injectable dermal filler. Pipeline products include using the microsphere technology for bulking the esophageal sphincter (ArteFlux) and the urinary sphincter (ArteSure) to treat gastro esophageal reflux disease and stress urinary incontinence, respectively. Other potential applications include spinal disc repair, treating snoring by bulking the soft palate and respiratory tissue, adding cushioning to the bottom of the foot to treat pain, and treatments for fecal incontinence, Artes says. ArteFill, the firm's only commercial product, gained PMA approval in October for correcting smile lines (1"The Gray Sheet" Jan. 1, 2007, p. 12)...
Introducing Spheris Medical
Artes Medical creates a wholly-owned subsidiary called Spheris Medical June 12 to develop non-aesthetic applications of its ArteFill non-resorbable, injectable dermal filler. Pipeline products include using the microsphere technology for bulking the esophageal sphincter (ArteFlux) and the urinary sphincter (ArteSure) to treat gastro esophageal reflux disease and stress urinary incontinence, respectively. Other potential applications include spinal disc repair, treating snoring by bulking the soft palate and respiratory tissue, adding cushioning to the bottom of the foot to treat pain, and treatments for fecal incontinence, Artes says. ArteFill, the firm's only commercial product, gained PMA approval in October for correcting smile lines (1"The Gray Sheet" Jan. 1, 2007, p. 12)...
Mentor Injects Dermal Filler Pipeline With Genzyme R&D
Mentor will market future Genzyme-developed hyaluronic acid dermal filler products to complement its existing Puragen hyaluronic acid device platform under a partnership agreement announced Oct. 30